{"id":65817,"date":"2026-02-03T17:57:03","date_gmt":"2026-02-03T12:27:03","guid":{"rendered":"https:\/\/www.nextias.com\/ca\/?p=65817"},"modified":"2026-02-03T17:58:57","modified_gmt":"2026-02-03T12:28:57","slug":"india-global-biopharma-hub","status":"publish","type":"post","link":"https:\/\/www.nextias.com\/ca\/current-affairs\/03-02-2026\/india-global-biopharma-hub","title":{"rendered":"Transforming India into a Global Biopharma Hub"},"content":{"rendered":"\n<p><strong>Syllabus: GS3\/Economy<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Context<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Union Budget 2026\u201327<\/strong> proposed the <strong>Biopharma SHAKTI<\/strong> with an outlay of Rs. 10,000 crores over <strong>five years,<\/strong> aimed at strengthening India\u2019s ecosystem for <strong>production of biologics and biosimilars.<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Biopharma<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biopharma, or biopharmaceuticals, <\/strong>refers to the part of the <strong>pharmaceutical industry <\/strong>that focuses on developing and manufacturing medicines<strong> using living biological systems,<\/strong> rather than relying solely on chemical synthesis.\n<ul class=\"wp-block-list\">\n<li><strong>Biopharma medicines are produced through<\/strong> biological organisms, such as human cells, fungi, or microbes.\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Some examples of biopharmaceuticals include<\/strong> vaccines, antibody treatments, gene therapies, cell implants, modern insulin, and recombinant protein drugs.<\/li>\n\n\n\n<li><strong>Government\u2019s Aim: <\/strong>Transforming India into a leading global biopharma industry and capturing 5% of the global biopharmaceutical market share.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Key Budget Announcements for Biopharma<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Biopharma SHAKTI:<\/strong> The initiative is designed to support domestic development and manufacturing of high-value biopharmaceutical products and enhance India\u2019s competitiveness in global biologics supply chains.<\/li>\n\n\n\n<li><strong>Establishment of National Institutes: <\/strong>Establishment of three new National Institutes of Pharmaceutical Education and Research (NIPERs) and the upgradation of seven existing NIPERs.\n<ul class=\"wp-block-list\">\n<li>This measure seeks to address the growing requirement for highly specialised human resources in biopharma research, development, manufacturing and regulation.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Strengthening of Research Ecosystem: <\/strong>Creation of a large-scale <strong>clinical research ecosystem, <\/strong>with a proposal to develop over 1,000 accredited clinical trial sites across the country.\n<ul class=\"wp-block-list\">\n<li>This is expected to significantly improve India\u2019s capacity to conduct advanced clinical trials for biologics and biosimilars.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Regulatory Framework: <\/strong>Enhancing the capacity of the Central Drugs Standard Control Organisation (CDSCO) through the induction of specialised scientific and technical personnel.\n<ul class=\"wp-block-list\">\n<li>The focus is on improving regulatory efficiency, aligning approval timeframes with global standards.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>India\u2019s Pharmaceutical Sector<\/strong><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img data-dominant-color=\"acc2d3\" data-has-transparency=\"true\" loading=\"lazy\" decoding=\"async\" width=\"445\" height=\"417\" src=\"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2026\/02\/image-19.png\" alt=\"India\u2019s Pharmaceutical Sector\" class=\"has-transparency wp-image-65818\" style=\"--dominant-color: #acc2d3; aspect-ratio:1.0671862704687676;width:280px;height:auto\" srcset=\"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2026\/02\/image-19.png 445w, https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2026\/02\/image-19-300x281.png 300w\" sizes=\"auto, (max-width: 445px) 100vw, 445px\" \/><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\"><strong>Government Initiatives to Strengthen India\u2019s Biopharma Sector<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>National Biopharma Mission (NBM): <\/strong>The NBM \u2013 Innovate in India (i3) was launched in <strong>2017<\/strong> with an aim of transforming India into a <strong>$100 billion<\/strong> leading <strong>global biotech industry by 2025.\u00a0<\/strong>\n<ul class=\"wp-block-list\">\n<li>It is co-funded by the <strong>World Bank<\/strong> and implemented by the <strong>Biotechnology Industry Research Assistance Council (BIRAC).<\/strong><\/li>\n\n\n\n<li>The mission focuses on the development of new vaccines, bio-therapeutics, diagnostics and medical devices.\u00a0<\/li>\n\n\n\n<li>The mission also aims to make <strong>drugs more affordable and accessible.<\/strong><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>BIRAC-led Biotech Innovation Support:<\/strong> BIRAC was established in <strong>2012 <\/strong>under the Department of Biotechnology (DBT), supports innovation through funding schemes, incubation infrastructure and mentorship.\u00a0<\/li>\n\n\n\n<li><strong>Manufacturing and Industrial Strengthening Measures: <\/strong>Government has implemented schemes such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Strengthening of Pharmaceutical Industry (SPI) scheme and the Bulk Drug Parks Scheme.\u00a0<\/li>\n\n\n\n<li><strong>Promotion of Research and Innovation in Pharma-MedTech (PRIP):<\/strong> The PRIP scheme, launched in 2023 seeks to transform India into an innovation-driven and globally competitive Pharma-MedTech sector.\u00a0<\/li>\n\n\n\n<li><strong>BioE3 Policy: <\/strong>The BioE3 (Biotechnology for Economy, Environment and Employment) Policy was approved in 2024.\n<ul class=\"wp-block-list\">\n<li>The scheme aims to establish biomanufacturing, Bio-AI hubs and Biofoundry for a sustainable Viksit Bharat.\u00a0<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Bio-RIDE Scheme: <\/strong>The Bio-RIDE scheme launched in <strong>2024 <\/strong>merged<strong> two umbrella schemes<\/strong> of the <strong>DBT under one scheme:<\/strong> \u2018Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE)\u2019 with a new component namely Biomanufacturing and Biofoundry.\n<ul class=\"wp-block-list\">\n<li><strong>The scheme has three broad components: <\/strong>Biotechnology Research and Development (R&amp;D), Industrial &amp; Entrepreneurship Development (I&amp;ED), and Biomanufacturing and Biofoundry.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Conclusion<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>All these measures signal a deliberate and coordinated policy approach by the government to build a resilient biopharma ecosystem in India, spanning research, innovation, manufacturing and entrepreneurship.\u00a0<\/li>\n\n\n\n<li>The Biopharma SHAKTI scheme announced in the Union Budget 2026\u201327 therefore represents a key policy intervention in this direction.\u00a0<\/li>\n<\/ul>\n\n\n\n<p><strong>Source: <\/strong><a href=\"https:\/\/www.pib.gov.in\/PressNoteDetails.aspx?NoteId=157147&amp;ModuleId=3&amp;reg=3&amp;lang=2\" target=\"_blank\" rel=\"noopener\"><strong>PIB<\/strong><\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p><strong> Context <\/strong><\/p>\n<li class=\"ms-5\"> Union Budget 2026\u201327 proposed the Biopharma SHAKTI with an outlay of Rs. 10,000 crores over five years, aimed at strengthening India\u2019s ecosystem for production of biologics and biosimilars. <\/li>\n<p><\/p>\n<p><strong> Biopharma <\/strong><\/p>\n<li class=\"ms-5\"> Biopharma, or biopharmaceuticals, refers to the part of the pharmaceutical industry that focuses on developing and manufacturing medicines using living biological systems, rather than relying solely on chemical synthesis. <\/li>\n<li class=\"ms-5\"> Biopharma medicines are produced through biological organisms, such as human cells, fungi, or microbes. <\/li>\n<li class=\"ms-5\"> Some examples of biopharmaceuticals include vaccines, antibody treatments, gene therapies, cell implants, modern insulin, and recombinant protein drugs. <\/li>\n<p><a href=\" https:\/\/www.nextias.com\/ca\/current-affairs\/03-02-2026\/india-global-biopharma-hub \" class=\"btn btn-primary btn-sm float-end\">Read More<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-65817","post","type-post","status-publish","format-standard","hentry","category-current-affairs"],"acf":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/65817","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/comments?post=65817"}],"version-history":[{"count":3,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/65817\/revisions"}],"predecessor-version":[{"id":65822,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/65817\/revisions\/65822"}],"wp:attachment":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media?parent=65817"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/categories?post=65817"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/tags?post=65817"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}